Taiwan Liposome Company Nearing IPO After Round Of Financing
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - A cash injection from a U.S. venture capital firm may help a Taiwanese developer of drug delivery systems better compete on a global scale as it moves towards an initial public offering
You may also be interested in...
Sandoz, Taiwan’s TLC Ink Commercialization Deal For AmBisome Generic In U.S., EU
Sandoz will commercialize TLC’s liposomal amphotericin B product, a generic of Gilead’s AmBisome, in the U.S. and EU.
With An Eye On China’s Growing PAD Market, SciClone Teams Up With Taiwan Liposome Co.
Looking to take on Bayer/UCB’s Prostavasin and a local blockbuster from Beijing Tide Pharmaceutical Co., SciClone will jump into China’s peripheral arterial disease market with what it hopes is a differentiated product developed by TLC.
Korea's Ildong Pharmaceutical In Licensing Deal With Taiwan Liposome Firm To Sell Product In Korean Market
SEOUL - South Korea's Ildong Pharmaceutical has signed a marketing and distribution agreement with Taiwan Liposome Company to sell the latter's arterial vasodilator and platelet-aggregation inhibitor ProFlow (alprostadil) - available as a generic - in Korea